Latest News
From the Journals
Speakers at FDA advisory meetings have hidden conflicts
Nearly a quarter of public speakers at Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), meetings had conflicts of interest,...
Daily News Podcast
MDedge Daily News: Physician burnout needs more than yoga
And triple-agent therapy cuts COPD exacerbations.
From the Journals
Gene therapy for thalassemia normalizes hemoglobin
Ongoing results raise the prospect of a curative therapy for some beta thalassemia patients.
Conference Coverage
Impaired kidney function no problem for dabigatran reversal
ORLANDO – Idarucizumab, reversal agent for the anticoagulant dabigatran, worked fine in patients with renal dysfunction.
Conference Coverage
Early results favorable for combo TLR9 agonist + pembro in advanced melanoma
CHICAGO – The combination of pembrolizumab with CMP-001 is being evaluated as a strategy to overcome resistance to PD-1 blockade for patients with...
From the Journals
Meta-analysis finds no link between stroke and sickle cell trait
Neither crude stroke incidence rates nor regression analysis indicated a link between sickle cell trait in African Americans and stroke.
Feature
Company discontinues phase 3 ADAPT for mRCC
A second interim analysis of the trial comparing Rocapuldencel-T in combination with sunitinib to sunitinib monotherapy led Argos Therapeutics to...
Daily News Podcast
MDedge Daily News: Bridging medicine’s gender gap
And surgeries are driving up hospital costs.
Conference Coverage
VIDEO: Fix physician burnout? You need more than yoga
Physicians looking to renew their professional satisfaction and personal well-being should turn to an unlikely ally.
Conference Coverage
CO2 laser guided by confocal microscopy effectively treated superficial BCC
DALLAS – Over an average follow-up of 17 months, no recurrence has been detected clinically, dermoscopically, or by reflectance confocal...
From the Journals
Studies eye adjuvant therapy in locally advanced rectal cancer
After a median follow-up of more than 3 years, hazard ratios for overall survival were 0.44 and 0.50, favoring adjuvant chemotherapy.